JP2001513487A - 糖尿病治療用組成物及び治療方法 - Google Patents

糖尿病治療用組成物及び治療方法

Info

Publication number
JP2001513487A
JP2001513487A JP2000506830A JP2000506830A JP2001513487A JP 2001513487 A JP2001513487 A JP 2001513487A JP 2000506830 A JP2000506830 A JP 2000506830A JP 2000506830 A JP2000506830 A JP 2000506830A JP 2001513487 A JP2001513487 A JP 2001513487A
Authority
JP
Japan
Prior art keywords
composition
zinc
present
arachidonic acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000506830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513487A5 (enExample
Inventor
ケイ． ソン、ムン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2001513487A publication Critical patent/JP2001513487A/ja
Publication of JP2001513487A5 publication Critical patent/JP2001513487A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000506830A 1997-08-11 1998-08-06 糖尿病治療用組成物及び治療方法 Pending JP2001513487A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/909,240 US5834032A (en) 1997-08-11 1997-08-11 Compositions and methods for treating diabetes
US08/909,240 1997-08-11
PCT/US1998/016321 WO1999007224A1 (en) 1997-08-11 1998-08-06 Compositions and methods for treating diabetes

Publications (2)

Publication Number Publication Date
JP2001513487A true JP2001513487A (ja) 2001-09-04
JP2001513487A5 JP2001513487A5 (enExample) 2006-01-05

Family

ID=25426873

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000506830A Pending JP2001513487A (ja) 1997-08-11 1998-08-06 糖尿病治療用組成物及び治療方法

Country Status (6)

Country Link
US (1) US5834032A (enExample)
JP (1) JP2001513487A (enExample)
KR (1) KR100533618B1 (enExample)
CN (1) CN1216635C (enExample)
AU (1) AU8693098A (enExample)
WO (1) WO1999007224A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543798A (ja) * 2005-06-14 2008-12-04 ジオファーム オンコロジー， インコーポレイテッド チューブリンインヒビターであるインジブリン（Ｉｎｄｉｂｕｌｉｎ）の改良された薬物動態学を有する、経口投与のための薬剤組成物、及びその製造法
JPWO2015194447A1 (ja) * 2014-06-20 2017-04-20 サントリーホールディングス株式会社 糖代謝改善剤
JP2021500358A (ja) * 2017-10-20 2021-01-07 ノブメタファーマ カンパニー リミテッド 亜鉛塩、シクロ−ヒスプロおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
JP2021503483A (ja) * 2017-11-20 2021-02-12 ノブメタファーマ カンパニー リミテッド Ｃｈｐ（シクロ−ヒスプロ）を含む骨損失疾患の予防、改善または治療用組成物
JP2022533667A (ja) * 2019-05-17 2022-07-25 ノブメタファーマ カンパニー リミテッド 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
JP2023514658A (ja) * 2019-12-20 2023-04-07 ベクター・ビターレ・アイピー・リミテッド・ライアビリティ・カンパニー Ｉ型糖尿病の処置のための組成物および方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
WO2000018392A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
JP2001220348A (ja) * 1999-11-30 2001-08-14 Japan Science & Technology Corp 亜鉛（ｉｉ）有機錯体からなる血糖降下剤
CN101632669B (zh) * 2000-08-04 2011-05-18 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
JP4161031B2 (ja) * 2000-10-31 2008-10-08 独立行政法人産業技術総合研究所 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤
JP2003040784A (ja) * 2001-01-31 2003-02-13 Japan Science & Technology Corp 血糖降下剤
AU2003279761B2 (en) * 2002-10-02 2009-11-12 Luoxis Diagnostics, Inc. Diagnosis and monitoring of diseases
US6989025B2 (en) * 2002-10-04 2006-01-24 Boston Scientific Scimed, Inc. Extruded tubing with discontinuous striping
US7524517B2 (en) * 2003-01-17 2009-04-28 Uab Research Foundation Methods and compositions for P2X receptor calcium entry channels and other calcium entry mechanisms
US7144865B2 (en) * 2003-01-31 2006-12-05 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for treating obesity
KR20150080004A (ko) 2003-05-15 2015-07-08 앰피오 파마슈티컬스 인코퍼레이티드 Ｔ-세포 매개성 질환의 치료 방법
US20080249028A1 (en) * 2005-03-09 2008-10-09 Roger Williams Hospital Thyrotropin-Releasing Hormone Analogs and Method of Use
WO2008109445A1 (en) * 2007-03-02 2008-09-12 Preventive Nutrient Company, Inc. Compositions and methods for treating alzheimer's disease and dementia
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
AU2012323305B2 (en) 2011-10-10 2017-07-27 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
BR112014007657A2 (pt) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc dispositivos médicos implantáveis com tolerância imune aperfeiçoada e métodos para produção e implantação
MX355446B (es) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Tratamiento de rinitis.
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
CA2958080A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
HK1246669A1 (zh) 2015-06-22 2018-09-14 Ampio Pharmaceuticals, Inc. 人血清白蛋白低分子量组分在疾病治疗中的应用
CN105748564A (zh) * 2015-12-21 2016-07-13 天津中津药业股份有限公司 一种治疗糖尿病的药物组合物
US20210177932A1 (en) * 2017-12-11 2021-06-17 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for prevention and treatment of immune deficiency and inflammation
KR20190074746A (ko) * 2017-12-20 2019-06-28 주식회사 노브메타파마 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
US20200345728A1 (en) * 2019-04-30 2020-11-05 Novmetapharma Co., Ltd. Compositions and methods for treatment of atherosclerosis
US11547737B2 (en) 2020-06-17 2023-01-10 Novmetapharma Co., Ltd. Compositions and methods for treating virus infection
AU2021337209A1 (en) 2020-09-04 2023-02-23 Societe Des Produits Nestle Sa Compositions and methods for providing health benefits in an animal
KR20240032221A (ko) * 2022-08-31 2024-03-12 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 호흡기 질환의 예방, 개선 또는 치료용 조성물
KR20250066976A (ko) 2023-11-07 2025-05-14 주식회사 노브메타파마 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 당뇨병성 신증의 예방, 개선 또는 치료용 조성물
KR20250076353A (ko) 2023-11-21 2025-05-29 주식회사 노브메타파마 글루콘산 아연염 및 사이클로-히스프로를 유효성분으로 포함하는 비만 및 당뇨병의 예방, 개선 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6008038560, ＤＩＡＢＥＴＥＳ ＲＥＳ, 1996, ＶＯ．３１, Ｐ．１５７−１７０ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543798A (ja) * 2005-06-14 2008-12-04 ジオファーム オンコロジー， インコーポレイテッド チューブリンインヒビターであるインジブリン（Ｉｎｄｉｂｕｌｉｎ）の改良された薬物動態学を有する、経口投与のための薬剤組成物、及びその製造法
JP2013151574A (ja) * 2005-06-14 2013-08-08 Ziopharm Oncology Inc チューブリンインヒビターであるインジブリン（Ｉｎｄｉｂｕｌｉｎ）の改良された薬物動態学を有する、経口投与のための薬剤組成物、及びその製造法
JPWO2015194447A1 (ja) * 2014-06-20 2017-04-20 サントリーホールディングス株式会社 糖代謝改善剤
JP2021500358A (ja) * 2017-10-20 2021-01-07 ノブメタファーマ カンパニー リミテッド 亜鉛塩、シクロ−ヒスプロおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
JP7005050B2 (ja) 2017-10-20 2022-01-21 ノブメタファーマ カンパニー リミテッド 亜鉛塩、シクロ－ヒスプロおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
JP2021503483A (ja) * 2017-11-20 2021-02-12 ノブメタファーマ カンパニー リミテッド Ｃｈｐ（シクロ−ヒスプロ）を含む骨損失疾患の予防、改善または治療用組成物
JP2022533667A (ja) * 2019-05-17 2022-07-25 ノブメタファーマ カンパニー リミテッド 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
JP7271016B2 (ja) 2019-05-17 2023-05-11 ノブメタファーマ カンパニー リミテッド 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
JP2023514658A (ja) * 2019-12-20 2023-04-07 ベクター・ビターレ・アイピー・リミテッド・ライアビリティ・カンパニー Ｉ型糖尿病の処置のための組成物および方法
JP7755317B2 (ja) 2019-12-20 2025-10-16 ベクター・ビターレ・アイピー・リミテッド・ライアビリティ・カンパニー Ｉ型糖尿病の処置のための組成物および方法

Also Published As

Publication number Publication date
CN1265560A (zh) 2000-09-06
US5834032A (en) 1998-11-10
KR20010022786A (ko) 2001-03-26
WO1999007224A1 (en) 1999-02-18
KR100533618B1 (ko) 2005-12-06
AU8693098A (en) 1999-03-01
CN1216635C (zh) 2005-08-31
HK1031174A1 (en) 2001-06-08

Similar Documents

Publication Publication Date Title
JP2001513487A (ja) 糖尿病治療用組成物及び治療方法
US4962121A (en) Method and composition for treating neurological diseases such as migraine
US8815311B2 (en) Methods for improving thyroid function in a subject
IL182950A (en) Liposomal suspension for oral glutathione administration
US20180296594A1 (en) Solid oral dosage form for breast symptoms
WO1995017889A1 (en) Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
EP3081097A1 (en) Composition for the treatment of infertility
WO2014135956A1 (en) Composition for use in the treatment of polycystic ovary syndrome
EP4288045A1 (en) Methods for inhibiting the progression of neurodegenerative diseases
KR100304312B1 (ko) 아연이보충된전립선추출물
US7144865B2 (en) Compositions and methods for treating obesity
AU2022313207A1 (en) Methods for inhibiting the progression of oxidative retinal diseases
US20050176829A1 (en) Methods for treating hypothyroidism
JP2022540862A (ja) 高濃度インスリン製剤
US20050009919A1 (en) Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
JP2862676B2 (ja) 亜鉛を補充された前立腺抽出物
JP6792848B2 (ja) 代謝改善剤
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
WO2024049497A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
CN118019529A (zh) 抑制氧化性视网膜疾病进展的方法
JP2731063B2 (ja) 卵巣欠落によるのぼせ治療剤
BE829197A (fr) Compositions anti-inflammatoires, leur preparation et leur utilisation
JP2006232815A (ja) 血中ＣｏＱ１０量を増加させる医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050513

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070511

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090916

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20091020

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100326

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100930

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101001